Biodel (BIOD) has risen sharply, recording gains of 19.91% in the past 4 weeks. However, the stock has corrected -5.76% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 18.68% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
The stock has recorded a 20-day Moving Average of 1.8% and the 50-Day Moving Average is 12.52%. Biodel (NASDAQ:BIOD): stock turned positive on Friday. Though the stock opened at $0.383, the bulls momentum made the stock top out at $0.4279 level for the day. The stock recorded a low of $0.383 and closed the trading day at $0.3909, in the green by 0.21%. The total traded volume for the day was 561,465. The stock had closed at $0.3901 in the previous days trading.
The company Insiders own 3.9% of Biodel shares according to the proxy statements. Institutional Investors own 11.13% of Biodel shares.
Biodel Inc. is a specialty pharmaceutical company. The Company focuses on the development and commercialization of treatments for diabetes. The Company is engaged in developing product candidates by applying its formulation technologies to existing drugs to improve their therapeutic profiles. The Company is engaged in developing room temperature stable glucagon presentations for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia or low concentrations of blood glucose. The Company is also developing insulin formulations for Type 1 and Type 2 diabetes patients. The Companys product pipeline includes RHI-Based Ultra-Rapid-Acting Insulin, Analog-Based Ultra-Rapid-Acting Insulin, Concentrated Ultra-Rapid-Acting Insulin and Glucagon.